Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria.

BACKGROUND Intervention studies in microalbuminuric type 2 diabetic patients have demonstrated that it is possible to avoid progression to overt diabetic nephropathy and even to achieve regression to normoalbuminuria. However, the long-term impact of stabilization/regression in albuminuria on decline in glomerular filtration rate (GFR) has not been established. METHODS 151 patients with type 2 diabetes and microalbuminuria at baseline in whom GFR was measured at least three times during 7.8 years of follow-up were divided into three groups according to the level of albuminuria during follow-up. Overt nephropathy was diagnosed as a urinary albumin excretion rate (AER) >300 mg/24 h and remission to normoalbuminuria was defined as an AER <30 mg/24 h at the last examination. RESULTS During follow-up, 46 patients achieved remission to normoalbuminuria, 58 remained microalbuminuric and 47 patients progressed to overt nephropathy. The mean (+/- SE) yearly decline in GFR was lowest (2.3+/-0.4 ml/min/year) in patients who obtained remission, in comparison with patients remaining microalbuminuric, in whom the decline was 3.7+/-0.4 ml/min/year, and patients progressing to overt nephropathy, who had a decline in GFR of 5.4+/-0.5 ml/min/year (ANOVA, P<0.001). Start of antihypertensive treatment during follow-up was strongly associated with remission to normoalbuminuria [odds ratio: 2.32; 95% confidence interval (CI): 1.09-4.93] whereas a decrease in HbA(1c) by 1% increased the probability for remission (odds ratio: 1.48; 95% CI: 1.11-1.97). CONCLUSIONS Remission to normoalbuminuria was associated with a decreased GFR decline during 7.8 years of follow-up in type 2 diabetic patients with microalbuminuria. Antihypertensive therapy and improved glycaemic control were independent predictors for remission.

[1]  L. Melton,et al.  Epidemiology of Persistent Proteinuria in Type II Diabetes Mellitus: Population-Based Study in Rochester, Minnesota , 1988, Diabetes.

[2]  D. de Zeeuw,et al.  Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. , 1994, Kidney international. Supplement.

[3]  D. DeMets,et al.  Proteinuria in diabetes. , 1988, Archives of internal medicine.

[4]  F. Nuttall,et al.  Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. , 2000, Diabetes care.

[5]  J. Chan,et al.  Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. , 2000, Kidney international.

[6]  M. Lishner,et al.  Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. , 1996, Archives of internal medicine.

[7]  G. Beck,et al.  Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. , 1996, The New England journal of medicine.

[8]  O. Tomonaga,et al.  Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients , 1997, Diabetologia.

[9]  G. Gambaro,et al.  Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. , 2001, Diabetes, nutrition & metabolism.

[10]  C. Stehouwer,et al.  Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure , 1998, Diabetologia.

[11]  B. Feldt-Rasmussen,et al.  Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. , 1985, Scandinavian journal of clinical and laboratory investigation.

[12]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[13]  R. Klein,et al.  Proteinuria in Mexican Americans and Non-Hispanic Whites With NIDDM , 1989, Diabetes Care.

[14]  H. Parving,et al.  Smoking and progression of diabetic nephropathy in type 1 diabetes. , 2003, Diabetes care.

[15]  Jahangir Ahmad,et al.  Effective Postponement of Diabetic Nephropathy With Enalapril in Normotensive Type 2 Diabetic Patients With Microalbuminuria , 1997, Diabetes Care.

[16]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[17]  G. Viberti,et al.  Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect , 2002, Circulation.

[18]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[19]  H. Parving,et al.  Reduction in albuminuria predicts diminished progression in diabetic nephropathy. , 1994, Kidney international. Supplement.

[20]  J. Bröchner-Mortensen,et al.  Individual determination of glomerular filtration rate from plasma creatinine. , 1976, Scandinavian journal of clinical and laboratory investigation.

[21]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[22]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.